Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 15 2024 - 8:00AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of October 2024
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Alterity Therapeutics Limited |
| |
|
|
| |
By: |
/s/ Geoffrey P. Kempler |
| |
|
Geoffrey P. Kempler |
| |
|
Chairman |
Date:
October 15, 2024
2
Exhibit 99.1
Alterity Therapeutics to Participate
in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
MELBOURNE, AUSTRALIA AND SAN FRANCISCO,
USA – 14 October 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),
a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David
Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on
Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 October 2024 at 4:30 a.m. AEDT in Australia.
A link to the live and archived webcast
may be accessed on the Alterity website under the Investors section: Events and Presentations. An archive of the webcast will be
available for three months.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical
stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s
lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat
the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For
further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Alterity Therapeutics (PK) (USOTC:PRNAF)
Historical Stock Chart
From Dec 2024 to Jan 2025
Alterity Therapeutics (PK) (USOTC:PRNAF)
Historical Stock Chart
From Jan 2024 to Jan 2025
